Precision Medicine’s value is undeniable. But what about its financial impact? And how should we assess its value?

Read the views of Panaxea co-founder dr. Lotte Steuten, as presented at the 2017 Precision Medicine World Conference in Silicon Valley. This presentation will cover the unsustainable economics at play, reimbursement challenges and policies, and cost-based pricing versus value-based pricing, from a patient, pharma, payor, and molecular diagnostics perspective.